|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Baniak N, Senger JL, Ahmed S, Kanthan SC
and Kanthan R: Gastric biomarkers: A global review. World J Surg
Oncol. 14:2122016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Muz B, de la Puente P, Azab F and Azab AK:
The role of hypoxia in cancer progression, angiogenesis,
metastasis, and resistance to therapy. Hypoxia (Auckl). 3:83–92.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Guo X, Li D, Chen Y, An J, Wang K, Xu Z,
Chen Z and Xing J: SNP rs2057482 in HIF1A gene predicts clinical
outcome of aggressive hepatocellular carcinoma patients after
surgery. Sci Rep. 5:118462015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fraga A, Ribeiro R, Principe P, Lobato C,
Pina F, Maurício J, Monteiro C, Sousa H, da Silva F Calais, Lopes C
and Medeiros R: The HIF1A functional genetic polymorphism at locus
+1772 associates with progression to metastatic prostate cancer and
refractoriness to hormonal castration. Eur J Cancer. 50:359–365.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shyu KG, Hsu FL, Wang MJ, Wang BW and Lin
S: Hypoxia-inducible factor 1alpha regulates lung adenocarcinoma
cell invasion. Exp Cell Res. 313:1181–1191. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang W, Zhang H and Xing L: Antisense
oligonucleotide of hypoxia-inducible factor-1alpha suppresses
growth and tumorigenicity of lung cancer cells A549. J Huazhong
Univ Sci Technolog Med Sci. 26:448–450. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Baba Y, Nosho K, Shima K, Irahara N, Chan
AT, Meyerhardt JA, Chung DC, Giovannucci EL, Fuchs CS and Ogino S:
HIF1A overexpression is associated with poor prognosis in a cohort
of 731 colorectal cancers. Am J Pathol. 176:2292–2301. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Espinosa I, José Carnicer M, Catasus L,
Canet B, D'angelo E, Zannoni GF and Prat J: Myometrial invasion and
lymph node metastasis in endometrioid carcinomas: Tumor-associated
macrophages, microvessel density, and HIF1A have a crucial role. Am
J Surg Pathol. 34:1708–1714. 2010.PubMed/NCBI
|
|
10
|
Deb S, Johansson I, Byrne D, Nilsson C,
Investigators k Constable L, Fjällskog ML, Dobrovic A, Hedenfalk I
and Fox S: Nuclear HIF1A expression is strongly prognostic in
sporadic but not familial male breast cancer. Mod Pathol.
27:1223–1230. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hoffmann AC, Mori R, Vallbohmer D,
Brabender J, Klein E, Drebber U, Baldus SE, Cooc J, Azuma M,
Metzger R, et al: High expression of HIF1a is a predictor of
clinical outcome in patients with pancreatic ductal adenocarcinomas
and correlated to PDGFA, VEGF, and bFGF. Neoplasia. 10:674–679.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vainrib M, Golan M, Amir S, Dang DT, Dang
LH, Bar-Shira A, Orr-Urtreger A, Matzkin H and Mabjeesh NJ: HIF1A
C1772T polymorphism leads to HIF-1α mRNA overexpression in prostate
cancer patients. Cancer Biol Ther. 13:720–726. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nakai H, Watanabe Y, Ueda H and Hoshiai H:
Hypoxia inducible factor 1-alpha expression as a factor predictive
of efficacy of taxane/platinum chemotherapy in advanced primary
epithelial ovarian cancer. Cancer Lett. 251:164–167. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhong H, De Marzo AM, Laughner E, Lim M,
Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL and Simons
JW: Overexpression of hypoxia-inducible factor 1alpha in common
human cancers and their metastases. Cancer Res. 59:5830–5835.
1999.PubMed/NCBI
|
|
15
|
Talks KL, Turley H, Gatter KC, Maxwell PH,
Pugh CW, Ratcliffe PJ and Harris AL: The expression and
distribution of the hypoxia-inducible factors HIF-1alpha and
HIF-2alpha in normal human tissues, cancers, and tumor-associated
macrophages. Am J Pathol. 157:411–421. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Minervini G, Quaglia F and Tosatto SC:
Insights into the proline hydroxylase (PHD) family, molecular
evolution and its impact on human health. Biochimie. 116:114–124.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Place TL, Fitzgerald MP, Venkataraman S,
Vorrink SU, Case AJ, Teoh ML and Domann FE: Aberrant promoter CpG
methylation is a mechanism for impaired PHD3 expression in a
diverse set of malignant cells. PLoS One. 6:e146172011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhou Y, Liang QL, Ou WT, Liu QL, Zhang XN,
Li ZY and Huang X: Effect of stable transfection with PHD3 on
growth and proliferation of HepG2 cells in vitro and in vivo. Int J
Clin Exp Med. 7:2197–2203. 2014.PubMed/NCBI
|
|
19
|
Chen Y, Zhang HS, Fong GH, Xi QL, Wu GH,
Bai CG, Ling ZQ, Fan L, Xu YM, Qin YQ, et al: PHD3 Stabilizes the
Tight Junction Protein Occludin and Protects Intestinal Epithelial
Barrier Function. J Biol Chem. 290:20580–20589. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu QL, Liang QL, Li ZY, Zhou Y, Ou WT and
Huang ZG: Function and expression of prolyl hydroxylase 3 in
cancers. Arch Med Sci. 9:589–593. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rawluszko AA, Bujnicka KE, Horbacka K,
Krokowicz P and Jagodzinski PP: Expression and DNA methylation
levels of prolyl hydroxylases PHD1, PHD2, PHD3 and asparaginyl
hydroxylase FIH in colorectal cancer. BMC Cancer. 13:5262013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Peurala E, Koivunen P, Bloigu R,
Haapasaari KM and Jukkola-Vuorinen A: Expressions of individual
PHDs associate with good prognostic factors and increased
proliferation in breast cancer patients. Breast Cancer Res Treat.
133:179–188. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen S, Zhang J, Li X, Luo X, Fang J and
Chen H: The expression of prolyl hydroxylase domain enzymes are
up-regulated and negatively correlated with Bcl-2 in non-small cell
lung cancer. Mol Cell Biochem. 358:257–263. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Su Y, Loos M, Giese N, Hines OJ, Diebold
I, Görlach A, Metzen E, Pastorekova S, Friess H and Büchler P: PHD3
regulates differentiation, tumour growth and angiogenesis in
pancreatic cancer. Br J Cancer. 103:1571–1579. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tennant DA and Gottlieb E: HIF prolyl
hydroxylase-3 mediates alpha-ketoglutarate-induced apoptosis and
tumor suppression. J Mol Med (Berl). 88:839–849. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xue J, Li X, Jiao S, Wei Y, Wu G and Fang
J: Prolyl hydroxylase-3 is down-regulated in colorectal cancer
cells and inhibits IKKbeta independent of hydroxylase activity.
Gastroenterology. 138:606–615. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Andersen S, Donnem T, Stenvold H, Al-Saad
S, Al-Shibli K, Busund LT and Bremnes RM: Overexpression of the HIF
hydroxylases PHD1, PHD2, PHD3 and FIH are individually and
collectively unfavorable prognosticators for NSCLC survival. PLoS
One. 6:e238472011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Couvelard A, Deschamps L, Rebours V,
Sauvanet A, Gatter K, Pezzella F, Ruszniewski P and Bedossa P:
Overexpression of the oxygen sensors PHD-1, PHD-2, PHD-3, and FIH
Is associated with tumor aggressiveness in pancreatic endocrine
tumors. Clin Cancer Res. 14:6634–6639. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gossage L, Zaitoun A, Fareed KR, Turley H,
Aloysius M, Lobo DN, Harris AL and Madhusudan S: Expression of key
hypoxia sensing prolyl-hydroxylases PHD1, −2 and −3 in
pancreaticobiliary cancer. Histopathology. 56:908–920. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tanaka T, Li TS, Urata Y, Goto S, Ono Y,
Kawakatsu M, Matsushima H, Hirabaru M, Adachi T, Kitasato A, et al:
Increased expression of PHD3 represses the HIF-1 signaling pathway
and contributes to poor neovascularization in pancreatic ductal
adenocarcinoma. J Gastroenterol. 50:975–983. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rishi MT, Selvaraju V, Thirunavukkarasu M,
Shaikh IA, Takeda K, Fong GH, Palesty JA, Sanchez JA and Maulik N:
Deletion of prolyl hydroxylase domain proteins (PHD1, PHD3)
stabilizes hypoxia inducible factor-1 alpha, promotes
neovascularization and improves perfusion in a murine model of
hind-limb ischemia. Microvasc Res. 97:181–188. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Spanberger T, Berghoff AS, Dinhof C,
Ilhan-Mutlu A, Magerle M, Hutterer M, Pichler J, Wöhrer A, Hackl M,
Widhalm G, et al: Extent of peritumoral brain edema correlates with
prognosis, tumoral growth pattern, HIF1a expression and angiogenic
activity in patients with single brain metastases. Clin Exp
Metastasis. 30:357–368. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lee JW, Bae SH, Jeong JW, Kim SH and Kim
KW: Hypoxia-inducible factor (HIF-1)alpha: Its protein stability
and biological functions. Exp Mol Med. 36:1–12. 2004. View Article : Google Scholar : PubMed/NCBI
|
